ORCID Profile
0000-0003-2576-8780
Current Organisations
University of Oxford
,
Nanfang Hospital
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: IOP Publishing
Date: 26-09-2013
Publisher: American Chemical Society (ACS)
Date: 18-08-2022
Publisher: Wiley
Date: 13-11-2019
Abstract: Two-photon photodynamic therapy (TP-PDT) is emerging as a powerful strategy for stereotactic targeting of diseased areas, but ideal photosensitizers (PSs) are currently lacking. This work reports a smart PS with aggregation-induced emission (AIE) feature, namely DPASP, for TP-PDT with excellent performances. DPASP exhibits high affinity to mitochondria, superior photostability, large two-photon absorption cross section as well as efficient reactive oxygen species generation, enabling it to achieve photosensitization both in vitro and in vivo under two-photon excitation. Moreover, its capability of stereotactic ablation of targeted cells with high-precision is also successfully demonstrated. All these merits make DPASP a promising TP-PDT candidate for accurate ablation of abnormal tissues with minimal damages to surrounding areas in the treatment of various diseases.
Publisher: Wiley
Date: 10-10-2023
Abstract: High‐efficiency absorptivity is crucial for the construction of high‐performance luminescent materials, especially the long‐wavelength near‐infrared II (NIR‐II) materials, thus seeking an efficient and universal strategy to elevate the absorptivity is extremely important but is still an intractable challenge. In this work, we discovered a simple but efficient design strategy involving the introduction of gold(I) unit that could effectively elevate the absorptivity of aggregation‐induced emission luminogens (AIEgens). As a result of the efficient elevation of absorptivity, the representative AIE‐active TBTP‐Au showed more superior NIR‐II (1220 nm) luminescence, much higher photothermal conversion efficiency, and unique intracellular reactive oxygen species generating ability compared with that of the TBTP ligand. Take advantage of these improvements, the fabricated tumor‐targeting TBTP‐Au‐cRGD nanoparticles achieved specific NIR‐II tumorous imaging in vivo and exerted high‐efficiency cancer therapy via the synergistic chemotherapy and photothermal therapy. Thus, this work provides a new and efficient strategy to construct high‐absorption luminescent materials and demonstrates the great potential of gold(I)‐based AIEgens as multifunctional theranostic agents. This article is protected by copyright. All rights reserved
Publisher: Wiley
Date: 09-2020
Publisher: American Chemical Society (ACS)
Date: 03-05-2021
Abstract: Gold complexes have been recognized as potential anticancer agents against various kinds of diseases due to their inherent suppressions of antioxidant thioredoxin reductase (TrxR) activity. Herein, a powerful aggregation-induced emission luminogen (AIEgen), TBP-Au, was designed and synthesized by integrating an anticancer Au(I) moiety with an AIE-active photosensitizer (TBP), in which both the production and consumption routes of reactive oxygen species (ROS) were elaborately considered simultaneously to boost the anticancer efficacy. It has been demonstrated that TBP-Au could realize superior two-photon fluorescence imaging in tumor tissues with high resolution and deep penetration as well as long-term imaging in live animals due to its AIE property. In addition, the introduction of a special Au(I) moiety could tune the organelle specificity and efficiently facilitate the ROS-determined photodynamic therapy (PDT). More impressively, TBP-Au could efficiently eliminate cancer cells under light irradiation through the preconceived synergetic approaches from the PDT and the effective suppression of TrxR, demonstrating that TBP-Au holds great potential for precise cancer theranostics.
Publisher: Wiley
Date: 20-03-2023
Abstract: Small extracellular vesicles derived from human pluripotent stem cells (hPSC‐sEVs) have shown great application potential in regenerative medicine. To standardise its research and clinical application, the first set of guidelines on hPSC‐sEVs in China ‘Requirements for human pluripotent stem cell derived small extracellular vesicles’ was released by the Chinese Research Hospital Association on 28 December 2021 and came into effect on 1 January 2022. It was jointly drafted and agreed upon by the experts from the Chinese Society of Extracellular Vesicles. This standard specifies the technical requirements, test methods and regulations, packaging, instructions for use, labelling, storage, transportation, and waste handling for hPSC‐sEVs, which apply to the production and quality control of hPSC‐sEVs. We hope that the publication of these guidelines will make it one step closer to international standardisation of hPSC‐sEVs for research and application.
Publisher: American Chemical Society (ACS)
Date: 24-07-2023
Publisher: Royal Society of Chemistry (RSC)
Date: 2020
DOI: 10.1039/C9QM00732F
Abstract: A smart AIEgen has been developed to rapidly (5 minutes) and precisely differentiate fungal viability in a wash-free manner.
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Lei Zheng.